Structure Therapeutics Announces Results of 2026 Annual General Meeting of Shareholders

On June 17, 2026, Structure Therapeutics Inc. held its 2026 Annual General Meeting of Shareholders. During the meeting, shareholders voted on three key proposals. First, Ted W. Love, M.D., Raymond Stevens, Ph.D., and Daniel G. Welch were elected as Class III directors to serve until the 2029 Annual General Meeting. Second, the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. Finally, shareholders approved, on an advisory basis, the compensation of the company's named executive officers as disclosed in the proxy statement. As of the record date, April 20, 2026, there were 213,213,565 ordinary shares outstanding and entitled to vote. All proposals passed with the required majority of votes. The filing was signed by Matthew Lang, Chief Operating Officer and General Counsel, on June 18, 2026.